Pterostilbene chalcone compounds, their preparation methods and medical uses
By synthesizing pterostilbene chalcone compounds, the limitations of pterostilbene and paeonol in clinical applications were resolved, and a potent anti-inflammatory effect was achieved, which is suitable for the development of new anti-inflammatory drugs.
Patent Information
- Application Number
- CN202410426021.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-04-10
- Publication Date
- 2025-09-19
- Estimated Expiration
- 2044-04-10
AI Technical Summary
The clinical application of pterostilbene and paeonol is limited due to their easy oxidation, low bioavailability and poor water solubility. Chalcone compounds have weak activity and it is difficult to achieve good anti-inflammatory effects.
Pterostilbene chalcone compounds were designed and synthesized. By combining pterostilbene with paeonol, a series of novel structural compounds were formed, which enhanced the anti-inflammatory activity and improved the physicochemical properties. The compounds were prepared by a multi-step reaction involving acid chlorides, alkaline reagents and solvents.
Pterostilbene chalcone compounds significantly inhibit the activity of key inflammatory mediators such as cyclooxygenase, inducible nitric oxide synthase and nuclear factor κB, have excellent anti-inflammatory effects, and their inhibitory effects are better than indomethacin, making them suitable for development as new anti-inflammatory drugs.